Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 1
1983 2
1984 3
1985 1
1986 4
1987 3
1988 2
1989 4
1990 3
1991 3
1992 2
1993 3
1994 2
1995 2
1996 6
1997 4
1998 2
1999 8
2000 5
2001 7
2002 5
2003 8
2004 11
2005 7
2006 11
2007 15
2008 17
2009 16
2010 7
2011 12
2012 16
2013 20
2014 14
2015 24
2016 23
2017 34
2018 27
2019 28
2020 43
2021 49
2022 60
2023 62
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

538 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Spreen, 5BAuthor
Page 1
Vegan and Omnivorous High Protein Diets Support Comparable Daily Myofibrillar Protein Synthesis Rates and Skeletal Muscle Hypertrophy in Young Adults.
Monteyne AJ, Coelho MOC, Murton AJ, Abdelrahman DR, Blackwell JR, Koscien CP, Knapp KM, Fulford J, Finnigan TJA, Dirks ML, Stephens FB, Wall BT. Monteyne AJ, et al. J Nutr. 2023 Jun;153(6):1680-1695. doi: 10.1016/j.tjnut.2023.02.023. Epub 2023 Feb 22. J Nutr. 2023. PMID: 36822394 Free PMC article. Clinical Trial.
BACKGROUND: It remains unclear whether non-animal-derived dietary protein sources (and therefore vegan diets) can support resistance training-induced skeletal muscle remodeling to the same extent as animal-derived protein sources. METHODS: In Phase 1, 16 healthy young adults ( …
BACKGROUND: It remains unclear whether non-animal-derived dietary protein sources (and therefore vegan diets) can support resistance trainin …
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.
Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D, Lam CSP, Chioncel O, Diaz R, Filippatos G, Ponikowski P, Sliwa K, Voors AA, Kimmoun A, Novosadova M, Takagi K, Barros M, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G, Mebazaa A, Davison B. Pagnesi M, et al. J Am Coll Cardiol. 2023 Jun 6;81(22):2131-2144. doi: 10.1016/j.jacc.2023.03.426. J Am Coll Cardiol. 2023. PMID: 37257948 Clinical Trial.
The treatment benefit of high-intensity care vs usual care on the primary endpoint was consistent across the whole LVEF spectrum (interaction P with LVEF as a continuous variable = 0.372). Mean difference in the EQ-5D visual analog scale change from baseline to day 90 betw …
The treatment benefit of high-intensity care vs usual care on the primary endpoint was consistent across the whole LVEF spectrum (interactio …
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.
van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, de Man FS, Kok WEM, Bronzwaer PNA, Allaart CP, Nederveen AJ, van Rossum AC, Bakermans AJ, Handoko ML. van de Bovenkamp AA, et al. ESC Heart Fail. 2023 Oct;10(5):2998-3010. doi: 10.1002/ehf2.14418. Epub 2023 Aug 2. ESC Heart Fail. 2023. PMID: 37530098 Free PMC article. Clinical Trial.
The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m(2) ); with the diagnosis of HFpEF confirmed with (exercise) right heart catheterization either before or during the trial. ...There was no ch …
The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m(2 …
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D. Monk BJ, et al. Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3. Lancet Oncol. 2023. PMID: 36878237 Clinical Trial.
Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m(2) plus cispla …
Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either …
[Asthenic post-COVID syndrome].
Khaibullina DK, Maksimov YN. Khaibullina DK, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(3):61-69. doi: 10.17116/jnevro202312303161. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 36946399 Russian.
Before the start of the study, in addition to a physical examination, the patient's condition was assessed using the following questionnaires and scales: VAS for asthenia, subjective scale for assessing asthenia (MFI-20), L.D. Malkova, a questionnaire for the quality of life (EQ- …
Before the start of the study, in addition to a physical examination, the patient's condition was assessed using the following questionnaire …
Angina After Percutaneous Coronary Intervention: Patient and Procedural Predictors.
Collison D, Copt S, Mizukami T, Collet C, McLaren R, Didagelos M, Aetesam-Ur-Rahman M, McCartney P, Ford TJ, Lindsay M, Shaukat A, Rocchiccioli P, Brogan R, Watkins S, McEntegart M, Good R, Robertson K, O'Boyle P, Davie A, Khan A, Hood S, Eteiba H, Berry C, Oldroyd KG. Collison D, et al. Circ Cardiovasc Interv. 2023 Apr;16(4):e012511. doi: 10.1161/CIRCINTERVENTIONS.122.012511. Epub 2023 Mar 28. Circ Cardiovasc Interv. 2023. PMID: 36974680 Free PMC article. Clinical Trial.
Compared with patients with no angina at follow-up, they had lower baseline SAQ summary scores (69.4824.12 versus 50.2022.59, P<0.001) and EQ-5D-5L health index scores (0.840.15 versus 0.690.22, P<0.001). Pre-PCI fractional flow reserve (FFR) was lower among p …
Compared with patients with no angina at follow-up, they had lower baseline SAQ summary scores (69.4824.12 versus 50.2022.59, P<0.001) an …
Lanthanide Photocatalysis.
Qiao Y, Schelter EJ. Qiao Y, et al. Acc Chem Res. 2018 Nov 20;51(11):2926-2936. doi: 10.1021/acs.accounts.8b00336. Epub 2018 Oct 18. Acc Chem Res. 2018. PMID: 30335356
Among the lanthanides, we have focused on cerium because of the doublet to doublet 4f 5d excitation and emission, which affords good conservation of energy without losses through spin-state changes, as well as a large natural abundance of that element. ...This complex is a …
Among the lanthanides, we have focused on cerium because of the doublet to doublet 4f 5d excitation and emission, which affords good …
Base-Displaced Intercalated Structure of the 3-(2-Deoxy-beta-D-erythropentofuranosyl)-pyrimido[1,2-f]purine-6,10(3H,5H)-dione (6-oxo-M(1)dG) Lesion in DNA.
Fu Y, Christov PP, Kingsley PJ, Richie-Jannetta RM, Marnett LJ, Stone MP. Fu Y, et al. Chem Res Toxicol. 2023 Dec 18;36(12):1947-1960. doi: 10.1021/acs.chemrestox.3c00226. Epub 2023 Nov 21. Chem Res Toxicol. 2023. PMID: 37989274 Free PMC article.
The latter blocks DNA replication and is a substrate for error-prone mutagenic bypass by the Y-family DNA polymerase hpol eta. To examine structural consequences of 6-oxo-M(1)dG damage in DNA, we conducted NMR studies of 6-oxo-M(1)dG incorporated site-specifically i …
The latter blocks DNA replication and is a substrate for error-prone mutagenic bypass by the Y-family DNA polymerase hpol eta. To examine st …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. ...The reported HRQoL did not decline compared with a prepandemic assessment (m …
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clin …
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho A, Reynolds M, Sherif B, Heist RS. Wolf J, et al. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36822130
PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 symptoms, and EQ-5D-5L visual analogue scale (VAS) questionnaires. RESULTS: As of 6 January 2020, 27/28 1L and 65/69 2L(+) patients h …
PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 …
538 results